Isabella P. Baskova

Importance to Hirudotherapy

Isabella Baskova's 1986 discovery of destabilase fundamentally rewrote the pharmacology of leech therapy. Before Baskova, leech anticoagulant action was understood almost entirely as hirudin-mediated thrombin inhibition — preventing new clot formation. Baskova showed that the leech also actively dissolves clots already formed, and does so by a mechanism completely unknown elsewhere in biochemistry: cleavage of the isopeptide bonds that Factor XIII forms between fibrin chains to stabilize a mature thrombus. Plasmin, the body's natural fibrinolytic enzyme, can dissolve fresh clots but struggles with cross-linked aged thrombi. Destabilase cleaves precisely those cross-links plasmin cannot reach. The clinical implications of this finding emerged slowly because Cold War-era publication delays kept Baskova's work largely unknown in the West until the late 1990s. When her 1991 Biokhimiya paper was finally translated and indexed in PubMed in 2001, reconstructive surgeons and thrombosis researchers realized that the leech's apparent ability to 'rescue' venous-congested flaps was not solely an anticoagulant effect but also an active fibrinolytic one. Destabilase's resistance to standard plasminogen-activator-inhibitor (PAI-1) regulation also made it attractive as a research tool for thrombolytic drug development. Baskova's 2021 collaboration with Kurdyumov demonstrated that recombinant destabilase dissolves 7-day-old murine venous thrombi with efficacy comparable to fresh-clot tPA — a milestone for chronic DVT treatment. Now in her late 80s, Baskova continues to lecture at Moscow State University and remains an active correspondent with the European Hirudotherapy Society. ASH lists her as one of the four 'living founders' of modern molecular hirudotherapy, alongside Markwardt's surviving students, Roy Sawyer, and Andreas Michalsen.